Introduction
============

The *MDM2* gene maps to chromosome 12q14.3--q15.[@b1-ott-9-6211] The MDM2 protein forms a complex with the p53 protein, attenuates the activity of p53, and promotes the subsequent degradation of p53 by acting as a ubiquitin E3 ligase for p53.[@b2-ott-9-6211],[@b3-ott-9-6211] The abnormal expression of the *MDM2*/*TP53* genes is linked to carcinogenesis or malignant transformation.[@b2-ott-9-6211],[@b4-ott-9-6211],[@b5-ott-9-6211] Accumulating evidence supports the link between the alteration of protein structural/functional behavior and single-nucleotide polymorphisms (SNPs) within relative genes.[@b6-ott-9-6211]--[@b11-ott-9-6211] Multiple prediction or detection techniques, such as structural biology, computational platform, and molecular dynamic simulation, contribute to the investigation of identification and function of disease-associated SNPs.[@b6-ott-9-6211]--[@b11-ott-9-6211] The SNPs of rs2279744 (T309G or SNP309), rs3730485 (del1518^+/−^) and rs937283 (A2164G), have been identified in the human *MDM2* gene.[@b12-ott-9-6211],[@b13-ott-9-6211] Previous reports have shown that *MDM2* polymorphisms are associated with susceptibility to various clinical diseases, such as bladder cancer,[@b14-ott-9-6211] hepatocellular carcinoma,[@b15-ott-9-6211] myelodysplastic syndromes,[@b16-ott-9-6211] and leukemia.[@b17-ott-9-6211],[@b18-ott-9-6211]

Keratinization of the epidermal cells often leads to the occurrence of squamous cell carcinoma (SCC), which behaves as the uncontrolled growth of outer abnormal squamous cells of the epidermis.[@b19-ott-9-6211]--[@b21-ott-9-6211] Specific types of SCC, such as head and neck SCC (HNSCC), skin squamous cell carcinoma (SSCC), esophageal SCC (ESCC), oral SCC (OSCC), lung SCC (LSCC), and cervical squamous cell carcinoma (CSCC), have been described.[@b19-ott-9-6211]--[@b23-ott-9-6211]

The different effects of the genetic mutations within *MDM2* have been reported to be related to the carcinogenesis of specific SCC types. For example, a lower plasma MDM2 level was observed in laryngeal SCC patients with the GT genotype of *MDM2* rs2279744 than the TT genotype.[@b24-ott-9-6211] The prevalence of *MDM2* rs2279744 might be involved in OSCC onset, rather than increased OSCC risks.[@b25-ott-9-6211] Although several previous meta-analyses on the correlation between *MDM2* rs2279744 polymorphism and the risks of HNSCC, OSCC, or ESCC have been reported,[@b26-ott-9-6211]--[@b28-ott-9-6211] another systematic evaluation with enlarged statistical power is still meaningful. Moreover, the meta-analyses of the association between *MDM2* rs937283 and rs3730485 polymorphisms and SCC risks, or between the *MDM2* rs2279744 polymorphism and other SCC types, such as SSCC and CSCC, have not been reported yet. It was thus worthwhile carrying out an updated systematic review and meta-analysis, in order to reassess the genetic relationship between common *MDM2* polymorphisms (rs2279744, rs937283, and rs3730485) and the overall risks of SCC.

Materials and methods
=====================

Article search
--------------

We searched for potentially relevant articles (up to May 7, 2016) from seven electronic databases: PubMed, Web of Science, Cochrane, Scopus, Chinese National Knowledge Infrastructure (CNKI), Wanfang, and Weipu. The key terms were as follows: mouse double minute 2 homolog; proto-oncogene proteins c-mdm2; MDM2; MDM2 proto-oncogene, E3 ubiquitin protein ligase; human homolog of mouse double minute 2; murine double minute 2; polymorphism; mutation; SNP; single nucleotide polymorphism; T309G; rs2279744; A2164G; rs937283; del1518; rs3730485; G285C; rs117039649; squamous cell carcinoma; carcinoma, squamous cell; and SCC.

Article screening and data extraction
-------------------------------------

With the help of EndNote X7 software, potential articles were screened for eligibility according to our strict inclusion/exclusion criteria. Exclusion criteria were duplicated articles, review or conference abstract, not human or clinical data, not relevant to MDM2, not about SCC, meta-analysis, not relevant to mutation, lack of control data, and overlapped data. Eligible case--control studies needed to be linked to SCC risks and contain data on individual genotype numbers of *MDM2* rs2279744, rs937283, and rs3730485 polymorphisms. We independently extracted the following data: first author, year of publication, country, ethnicity, SNPs, sample sizes and genotype frequencies of case/control group, SCC type, source of control, genotyping assay, *P*-values of Hardy--Weinberg equilibrium (HWE), and test of control groups. A detailed discussion was required for the conflicting assessment.

Statistical analysis
--------------------

Pooled odds ratios (ORs) with 95% confidence intervals (CIs) and *P*-values of associations based on Mantel--Haenszel statistics were calculated by Stata 12.0 software (StataCorp LP, College Station, TX, USA). *P*\>0.05 was considered the exclusion of statistically significant difference between case and control groups. The *I*^2^ test (0%--100%) and *Q*-statistic were adopted to evaluate the potential heterogeneities across case--control studies. *I*^2^\>25% or *P*-value of *Q*-statistic \<0.1 was considered significant heterogeneity, and statistical analysis under a random-effect model and sensitivity analysis were conducted. Six genetic (allele, homozygote, heterozygote, dominant, recessive, and carrier) models were employed. Subgroup analyses by ethnicity, source of controls, HWE or SCC types were also performed. In addition, potential publication bias was assessed by analysis of Begg's funnel plots (continuity-corrected) and Egger's publication-bias plots.

Results
=======

Studies selected for meta-analysis
----------------------------------

[Figure 1](#f1-ott-9-6211){ref-type="fig"} shows a flow diagram of our article-search strategy. A total of 545 potentially relevant articles were retrieved initially from the databases: PubMed (n=95), Web of Science (n=260), Cochrane (n=0), Scopus (n=73), CNKI (n=54), Wanfang (N=44), and Weipu (n=19). A total of 378 articles were obtained after duplicates had been removed by the EndNote software, and then 336 articles were excluded by screening titles and abstracts according to the exclusion criteria. Specific information is shown in [Figure 1](#f1-ott-9-6211){ref-type="fig"}. Next, 42 full-text articles were assessed for eligibility; 16 articles were then excluded for lack of control data (n=10) and overlapped data (n=6). Finally, 26 independent articles with 7,987 SCC cases and 12,954 controls were selected for our meta-analysis.[@b4-ott-9-6211],[@b12-ott-9-6211],[@b13-ott-9-6211],[@b18-ott-9-6211],[@b24-ott-9-6211],[@b25-ott-9-6211],[@b29-ott-9-6211]--[@b48-ott-9-6211] We then carefully extracted the data and summarized the characteristics ([Table 1](#t1-ott-9-6211){ref-type="table"}).

Polymorphism rs2279744 of *MDM2* and SCC susceptibility
-------------------------------------------------------

A total of 25 case--control studies[@b4-ott-9-6211],[@b12-ott-9-6211],[@b13-ott-9-6211],[@b18-ott-9-6211],[@b24-ott-9-6211],[@b25-ott-9-6211],[@b30-ott-9-6211]--[@b48-ott-9-6211] were enrolled for the meta-analysis of *MDM2* rs2279744 and risks of SCC. As shown in [Table 2](#t2-ott-9-6211){ref-type="table"}, the results (G vs T, *I*^2^=70.0%, *P*\<0.001; GG vs TT, *I*^2^=59.1%, *P*\<0.001; TG vs TT, *I*^2^=72.9%, *P*\<0.001; TG + GG vs TT, *I*^2^=73.7%, *P*\<0.001; GG vs TT + TG, *I*^2^=36.3%, *P*=0.04; carrier G vs T, *I*^2^=31.5%, *P*=0.068) suggested that between-study heterogeneity existed for *MDM2* rs2279744. The random-effect model was thus applied for meta-analysis. The pooled results further showed that an increased SCC risk was observed under the allele model ([Table 2](#t2-ott-9-6211){ref-type="table"}, G vs T, OR 1.09, 95% CI 1--1.19; *P*=0.041), homozygote model (GG vs TT, OR 1.17, 95% CI 1.02--1.36; *P*=0.03), and recessive model (GG vs TT + TG, OR 1.18, 95% CI 1.07--1.30; *P*=0.001), but not other genetic models. Forest plots can be seen for meta-analysis of the allele ([Figure 2A](#f2-ott-9-6211){ref-type="fig"}), homozygote ([Figure 3A](#f3-ott-9-6211){ref-type="fig"}), heterozygote ([Figure 4A](#f4-ott-9-6211){ref-type="fig"}), dominant ([Figure 5A](#f5-ott-9-6211){ref-type="fig"}), and recessive ([Figure 6A](#f6-ott-9-6211){ref-type="fig"}) models. These data revealed that the GG genotype of *MDM2* rs2279744 was statistically associated with increased SCC susceptibility.

Furthermore, subgroup analyses by ethnicity (Asian/Caucasian), HWE (*P*\>0.05/*P*\<0.05), source of control (population-based/hospital-based), and SCC type (HNSCC/SSCC/ESCC/OSCC/CSCC/LSCC) were performed for all genetic models. As shown in [Table 3](#t3-ott-9-6211){ref-type="table"}, a significantly increased SCC risk was observed in the Asian population in four models (G vs T, OR 1.12, *P*=0.027; GG vs TT, OR 1.26, *P*=0.016; GG vs TT + TG, OR 1.25, *P*\<0.001; carrier G vs T, OR 1.08, *P*=0.023). Similar results were obtained in the HWE *P*\>0.05 group and the population-based group for the allele, homozygote, recessive, and carrier models ([Table 3](#t3-ott-9-6211){ref-type="table"}, all OR \>1, *P*\<0.05). These data further indicated an association between the GG genotype of *MDM2* rs2279744 and increased SCC susceptibility in the Asian population. The results of stratified analyses by SCC type showed that a significantly increased ESCC risk was observed for three models ([Table 4](#t4-ott-9-6211){ref-type="table"}; G vs T, OR 1.19, *P*\<0.001; GG vs TT, OR 1.46, *P*\<0.001; GG vs TT + TG, OR 1.48, *P*=0.005). In addition, an increased SSCC risk was observed in the G vs T model ([Table 4](#t4-ott-9-6211){ref-type="table"}, OR 1.16, *P*=0.022) and the TG + GG vs TT model (OR 1.22, *P*=0.028), while an increased LSCC risk was only observed in the TG + GG vs TT model ([Table 4](#t4-ott-9-6211){ref-type="table"}, OR 1.18, *P*=0.045). In contrast, no significant difference was observed for OSCC and CSCC group in any genetic models ([Table 4](#t4-ott-9-6211){ref-type="table"}, test of association, all *P*\>0.05). These data further suggested that patients with the GG genotype of *MDM2* rs2279744 appeared to be at a higher risk of developing ESCC in the Asian population.

Polymorphisms rs937283 and rs3730485 of *MDM2* and SCC susceptibility
---------------------------------------------------------------------

Next, pooled analysis for the association between the rs937283 and rs3730485 polymorphisms of *MDM2* and the risks of SCC was conducted ([Table 2](#t2-ott-9-6211){ref-type="table"}). A random-effect model was used for the comparison of G vs A, GG vs AA, AG vs AA, AG + GG vs AA, due to the presence of heterogeneity (all heterogeneity tests, *I*^2^\>50%), whereas a fixed-effect model was used for others. No significant difference was observed for any genetic models ([Table 2](#t2-ott-9-6211){ref-type="table"}, test of association, all *P*\>0.05). The data failed to provide strong evidence regarding the association between the rs937283 and rs3730485 polymorphisms of *MDM2* and overall SCC susceptibility.

*MDM2*/*TP53* mutations and SCC susceptibility
----------------------------------------------

The *MDM2* rs2279744 polymorphism has been reported to suppress the p53 pathway via the modulation of MDM2 expression.[@b2-ott-9-6211],[@b49-ott-9-6211] We also investigated the genetic relationship between SCC risks and *MDM2*/*TP53* mutations, including *MDM2*^+^/*TP53*^−^, *MDM2*^−^/*TP53*^+^, and *MDM2*^+^/*TP53*^+^. Specific genotype information is shown in [Table 5](#t5-ott-9-6211){ref-type="table"}. A random-effect model was used. The data in [Table 5](#t5-ott-9-6211){ref-type="table"} show significant differences for the *MDM2*^+^/*TP53*^+^ double mutation in the overall population (test of association, OR 1.52, 95% CI 1.19--1.95; *P*=0.001) and the Asian population (test of association, OR 1.49, 95% CI 1.06--2.11; *P*=0.022). However, no significant difference was observed for other mutations (test of association, all *P*\>0.05). According to our data, the combined effect of the *MDM2*/*TP53* double mutation may contribute to an increased SCC risk, especially in the Asian population.

Publication bias and sensitivity analysis
-----------------------------------------

The results of Begg's funnel plots and Egger's publication-bias plots demonstrated that the occurrence of large publication bias was excluded under all genetic models ([Tables 2](#t2-ott-9-6211){ref-type="table"} and [4](#t4-ott-9-6211){ref-type="table"}, all *P*\>0.05), apart from the mutations of *MDM2*^+^/*TP53*^−^ and *MDM2*^+^/*TP53*^+^ in the Caucasian group ([Table 4](#t4-ott-9-6211){ref-type="table"}, Egger's publication-bias plot, *P*\<0.05). Egger's funnel plots of publication bias for the allele ([Figure 2B](#f2-ott-9-6211){ref-type="fig"}), homozygote ([Figure 3B](#f3-ott-9-6211){ref-type="fig"}), heterozygote ([Figure 4B](#f4-ott-9-6211){ref-type="fig"}), dominant ([Figure 5B](#f5-ott-9-6211){ref-type="fig"}), and recessive ([Figure 6B](#f6-ott-9-6211){ref-type="fig"}) models of *MDM2* rs2279744 polymorphism are shown. With regard to the sensitivity analysis, compared with overall meta-analysis data, no significant difference for the pooled OR value was observed when each study was omitted sequentially ([Figure 2C](#f2-ott-9-6211){ref-type="fig"} for allele model of *MDM2* rs2279744; [Figure 3C](#f3-ott-9-6211){ref-type="fig"} for homozygote model; [Figure 4C](#f4-ott-9-6211){ref-type="fig"} for heterozygote model; [Figure 5C](#f5-ott-9-6211){ref-type="fig"} for dominant model; [Figure 6C](#f6-ott-9-6211){ref-type="fig"} for recessive model; data not shown for others). Consequently, these data suggested that our statistical results were credible.

Discussion
==========

More and more studies on the possible role of the *MDM2* rs2279744 polymorphism in the onset and development of cancer have been reported. Hu et al performed a meta-analysis based on 25 published case--control studies, and reported that *MDM2* rs2279744 seems to be associated with tumor susceptibility.[@b50-ott-9-6211] Chen et al reported that the *MDM2* rs2279744 polymorphism may be linked to an increased digestive tract cancer risk in the Asian population.[@b51-ott-9-6211] Here, we further focused on the potential effect of *MDM2* rs2279744 in susceptibility to overall SCC and specific SCC types, including HNSCC, SSCC, ESCC, OSCC, CSCC, and LSCC.

Several SCC-related meta-analyses have been carried out previously. A meta-analysis by Liu et al based on seven articles with 1,629 cases and 2,472 controls showed that the G allele of the *MDM2* rs2279744 polymorphism seemed to act as an important HNSCC protective factor in the Caucasian population, but not the Asian population.[@b26-ott-9-6211] However, in our meta-analysis, we were unable to observe a significant association between HNSCC susceptibility and *MDM2* rs2279744. How to explain this? Seven studies were enrolled in the meta-analysis of Liu et al.[@b13-ott-9-6211],[@b18-ott-9-6211],[@b25-ott-9-6211],[@b31-ott-9-6211],[@b33-ott-9-6211],[@b35-ott-9-6211],[@b37-ott-9-6211] Also, data for OSCC in five studies[@b13-ott-9-6211],[@b18-ott-9-6211],[@b25-ott-9-6211],[@b33-ott-9-6211],[@b35-ott-9-6211] were included as HNSCC. The disease in two studies[@b31-ott-9-6211],[@b37-ott-9-6211] was defined only as HNSCC. In our subgroup analysis, we tested the relationship between OSCC risk and *MDM2* rs2279744. One new study[@b41-ott-9-6211] was added in the new meta-analysis for HNSCC. We found that the *MDM2* rs2279744 polymorphism did not appear to be associated with OSCC susceptibility, which is partly consistent with the results of Xie et al.[@b27-ott-9-6211]

A meta-analysis by Chen et al based on six case--control studies, including 1,899 cases and 3,016 controls, showed that the *MDM2* rs2279744 polymorphism may be associated with increased risks of overall esophageal cancer, including SCC and adenocarcinoma, especially in the Asian population.[@b28-ott-9-6211] However, our meta-analysis only targeted the ESCCs. We thus removed one study on esophageal adenocarcinoma[@b52-ott-9-6211] and added another new published case--control study.[@b12-ott-9-6211] All cases in six case--control studies were Chinese patients, with a mean age of \>50 years and male:female ratio of \>50%. The GG genotype of *MDM2* rs2279744 was likely to confer an increased susceptibility to ESCC in elderly male patients in People's Republic of China. The influence of habits and customs, such as drinking or smoking, should be considered.

Considering the close association between *MDM2* and p53,[@b2-ott-9-6211]--[@b5-ott-9-6211] it is meaningful to investigate the role of gene--gene interaction between *MDM2* and *TP53* Arg72Pro polymorphism in SCC risks. In our meta-analysis, we observed a positive association between *MDM2*^+^/*TP53*^+^ double mutation and SCC susceptibility in overall or Asian populations. The underlying molecular mechanism on the effect of *MDM2* genetic variation in the incidence of ESCC remains unclear. The rs2279744 SNP within the promoter region of *MDM2* can lead to a T--G substitution at the 309 nucleotide site, which is closely linked to the high expression of the MDM2 protein via higher binding affinity with the transcriptional activator SP1, and thus enhances the degradation of p53.[@b2-ott-9-6211] It was possible that *MDM2* rs2279744 polymorphism is linked to the increased SCC risks, through influencing the role of p53 pathway in genomic stability and tumor prevention. Chen et al conducted a meta-analysis to investigate the relationship between positive MDM2 expression and clinicopathological characteristics of ESCC, and found that high MDM2 expression was associated with early primary tumor stage and increased risk of regional lymph node metastasis, but not the risk of distant metastasis.[@b53-ott-9-6211] Vlatković et al reported that loss of MTBP expression seems to be associated with reduced survival in some patients with HNSCC.[@b54-ott-9-6211] In addition, several reported studies have estimated the role of the interaction between the *MDM2*/*TP53* gene and several environmental factors, including smoking exposure, alcohol consumption, or human papillomavirus infections in SCC susceptibility.[@b13-ott-9-6211],[@b29-ott-9-6211],[@b38-ott-9-6211],[@b40-ott-9-6211],[@b41-ott-9-6211] For instance, rs2279744 and rs937283 of *MDM2* might be associated with the occurrence of OSCC patients with HPV16 L1 seropositivity.[@b13-ott-9-6211] However, due to the lack of sufficient data, we failed to carry out a subgroup analysis based on these environmental factors.

Our meta-analysis contained several limitations. Very few publications resulted in small sample sizes for the analysis of *MDM2* rs937283 and rs3730485. The possible effect of other unpublished studies on our negative conclusion should be taken into consideration. The same limitation of sample size existed in the meta-analysis of *MDM2*/*TP53* double mutation and several subgroup analyses of the *MDM2* rs2279744 polymorphism. Heterogeneity and potential publication bias may weaken our conclusion. Demographic features, lifestyle, or clinical characteristics were not considered, due to the lack of data. Larger and independent studies are required to validate the association between *MDM2*/*TP53* mutations and susceptibility to different types of SCC.

Conclusion
==========

Our updated meta-analysis demonstrated that there is a positive association between increased overall SCC risks and the *MDM2* rs2279744 polymorphism, rather than rs937283 or rs3730485. We further provided evidence that the GG genotype of *MDM2* rs2279744 is more likely to confer an increased genetic susceptibility to ESCC in the Asian population, particularly in Chinese. *MDM2* rs2279744 may be a valuable risk factor or diagnostic biomarker for patients with ESCC in People's Republic of China, and needs more supporting evidence.

**Disclosure**

The authors report no conflicts of interest in this work.

![Flow diagram of article-search strategy for meta-analysis.\
**Abbreviation:** SCC, squamous cell carcinoma.](ott-9-6211Fig1){#f1-ott-9-6211}
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![Meta-analysis of the association between *MDM2* rs2279744 and SCC susceptibility under the GG vs TT model.\
**Notes:** (**A**) Forest plot; (**B**) Egger's funnel plot of publication-bias; (**C**) sensitivity analysis. Weights are from random-effect analysis.\
**Abbreviations:** SCC, squamous cell carcinoma; OR, odds ratio; CI, confidence interval.](ott-9-6211Fig3){#f3-ott-9-6211}

![Meta-analysis of the association between *MDM2* rs2279744 and SCC susceptibility under the TG vs TT model.\
**Notes:** (**A**) Forest plot; (**B**) Egger's funnel plot of publication-bias; (**C**) sensitivity analysis. Weights are from random-effect analysis.\
**Abbreviations:** SCC, squamous cell carcinoma; OR, odds ratio; CI, confidence interval.](ott-9-6211Fig4){#f4-ott-9-6211}
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**Notes:** (**A**) Forest plot; (**B**) Egger's funnel plot of publication-bias; (**C**) sensitivity analysis. Weights are from random-effect analysis.\
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###### 

Characteristics of studies included for meta-analysis

  Study                              Country                      Ethnicity     SNPs        Case    SCC type      Control         Source of control   Genotyping assay   HUE *P*-value                                  
  ---------------------------------- ---------------------------- ------------- ----------- ------- ------------- --------------- ------------------- ------------------ --------------- ------------------------------ ----------
  Alhopuro et al[@b31-ott-9-6211]    Finland                      Caucasian     rs2279744   157     58/75/24      HNSCC           185                 56/98/31           PB              PCR-RFLP and sequencing        0.28
  Almquist et al[@b4-ott-9-6211]     USA                          Caucasian     rs2279744   559     234/261/64    SSCC            674                 323/284/67         PB              Sequenom platform              0.69
  Cao et al[@b43-ott-9-6211]         People's Republic of China   Asian         rs2279744   351     50/170/131    ESCC            642                 117/299/226        PB              PIRA-PCR                       0.3
  rs3730485                          351                          181/146/24    ESCC        642     310/285/47                                        0.09                                                              
  Chen et al[@b13-ott-9-6211]        USA                          Caucasian     rs2279744   325     146/132/47    OSCC            335                 112/165/58         HB              PCR-RFLP                       0.84
  rs937283                           325                          69/209/47     OSCC        335     114/169/52                                        0.41                                                              
  Er et al[@b30-ott-9-6211]          People's Republic of China   Asian         rs2279744   121     47/31/43      ESCC            142                 41/78/23           PB              PCR-RFLP                       0.16
  Hamid et al[@b25-ott-9-6211]       Mixed                        Asian         rs2279744   207     48/104/55     OSCC            116                 30/58/28           PB              PCR-RFLP                       
  Hong et al[@b33-ott-9-6211]        People's Republic of China   Asian         rs2279744   758     203/348/207   ESCC            1,420               418/711/291        PB              PCR-RFLP                       0.72
  Huang et al[@b40-ott-9-6211]       People's Republic of China   Asian         rs2279744   351     80/176/95     OSCC            1,272               274/653/345        PB              MALDI-TOF                      0.29
  Jiang et al[@b39-ott-9-6211]       People's Republic of China   Asian         rs2279744   96      44/35/17      CSCC            140                 30/84/26           PB              PCR-RFLP and sequencing        **0.02**
  Kohno et al[@b44-ott-9-6211]       Japan                        Asian         rs2279744   377     68/183/126    LSCC            325                 79/151/95          HB              Pyrosequencing                 0.22
  Li et al[@b46-ott-9-6211]          People's Republic of China   Asian         rs2279744   132     37/70/25      ESCC            132                 47/71/14           PB              PCR-RFLP                       0.09
  Liu et al[@b34-ott-9-6211]         USA                          Caucasian     rs2279744   423     178/186/59    LSCC            1,360               530/626/204        HB              TaqMan assay sequencing        0.39
  Loginov et al[@b38-ott-9-6211]     Russia                       Caucasian     rs2279744   59      50/9/0        LSCC            160                 156/4/0            PB              PCR-RFLP                       0.87
  Ma et al[@b42-ott-9-6211]          People's Republic of China   Asian         rs2279744   226     49/119/58     ESCC            226                 50/118/58          PB              PCR-RFLP                       0.49
  rs3730485                          226                          120/91/15     ESCC        226     118/92/16                                         0.74                                                              
  Misra et al[@b18-ott-9-6211]       India                        Asian         rs2279744   297     70/147/80     OSCC            328                 59/181/88          PB              PCR-RFLP                       **0.04**
  Nakashima et al[@b37-ott-9-6211]   Japan                        Asian         rs2279744   103     29/46/28      HNSCC           120                 37/50/33           PB              Sequencing and real-time PCR   0.07
  Nan et al[@b47-ott-9-6211]         USA                          Caucasian     rs2279744   281     117/119/45    SSCC            851                 380/356/115        PB              PCR-RFLP                       **0.03**
  Park et al[@b36-ott-9-6211]        South Korea                  Asian         rs2279744   270     57/128/85     LSCC            582                 122/299/161        PB              PCR-RFLP                       0.44
  Roszak et al[@b32-ott-9-6211]      Poland                       Caucasian     rs2279744   379     139/169/71    CSCC            481                 202/204/75         PB              PCR-RFLP and sequencing        0.05
  Singhal et al[@b45-ott-9-6211]     India                        Asian         rs2279744   182     63/74/45      CSCC            182                 108/52/22          PB              PCR-RFLP and sequencing        **0.00**
  Tu et al[@b35-ott-9-6211]          People's Republic of China   Asian         rs2279744   189     44/93/52      OSCC            116                 29/55/32           PB              Sequencing                     0.58
  Yang et al[@b29-ott-9-6211]        People's Republic of China   Asian         rs937283    307     163/126/18    ESCC            311                 161/126/24         PB              TaqMan assay                   0.92
  Yu et al[@b41-ott-9-6211]          USA                          Caucasian     rs2279744   1,083   463/486/134   HNSCC           1,090               488/472/130        PB              PCR-RFLP                       0.33
  rs937283                           1,078                        369/522/187   HNSCC       1,089   355/529/205                   TaqMan assay        0.75                                                              
  Zhang et al[@b12-ott-9-6211]       People's Republic of China   Asian         rs2279744   132     37/70/25      ESCC            132                 47/71/14           PB              PCR-RFLP                       0.09
  rs3730485                          132                          17/59/56      ESCC        132     13/48/71                                          0.26                                                              
  Zhang et al[@b48-ott-9-6211]       People's Republic of China   Asian         rs2279744   476     113/241/122   LSCC            1,420               418/711/291        PB              ARMS-PCR                       0.72
  Zhou et al[@b24-ott-9-6211]        People's Republic of China   Asian         rs2279744   146     37/58/51      Laryngeal SCC   212                 35/109/68          PB              Pyrosequencing                 0.43

**Note:** *P*\<0.05 in bold.

**Abbreviations:** SNPs, single-nucleotide polymorphisms; M, major allele; m, minor allele; HNSCC, head and neck squamous cell carcinoma; SSCC, skin SCC; ESCC, esophageal SCC; OSCC, oral SCC; LSCC, lung SCC; CSCC, cervical SCC; PB, population-based; HB, hospital-based; PCR-RFLP, polymerase chain-reaction restriction fragment-length polymorphism; PIRA-PCR, primer-introduced restriction-analysis PCR; MALDI-TOF, matrix-assisted laser desorption/ionization time of flight; ARMS-PCR, amplification refractory mutation-system (tetra-primer) PCR; HUE, Hardy--Weinberg equilibrium.

###### 

Meta analysis of the association between *MDM2* polymorphisms (rs2279744, rs937283, and rs3730485) and SCC susceptibility

  SNP         Comparison        No of case-control studies   Case/control total sample size   Test of association   Heterogeneity   Model       Begg[a](#tfn3-ott-9-6211){ref-type="table-fn"}   Egger                                
  ----------- ----------------- ---------------------------- -------------------------------- --------------------- --------------- ----------- ------------------------------------------------ --------- --- ------ ------- ------- -------
  rs2279744   G vs T            25                           7,680/12,643                     1.09                  1--1.19         **0.041**   70                                               \<0.001   R   0.05   0.963   0.43    0.671
  rs2279744   GG vs TT          24                           7,621/12,483                     1.17                  1.02--1.36      **0.030**   59.1                                             \<0.001   R   0.05   0.96    −0.33   0.744
  rs2279744   TG vs TT          25                           7,680/12,643                     1                     0.87--1.15      0.975       72.9                                             \<0.001   R   0.79   0.427   −0.48   0.637
  rs2279744   TG + GG vs TT     25                           7,680/12,643                     1.06                  0.92--1.21      0.422       73.7                                             \<0.001   R   0.47   0.64    −0.18   0.861
  rs2279744   GG vs TT + TG     24                           7,621/12,483                     1.18                  1.07--1.3       **0.001**   36.3                                             0.04      R   0.74   0.457   0.52    0.607
  rs2279744   carrier G vs T    25                           7,680/12,643                     1.06                  1--1.13         0.064       31.5                                             0.068     R   0.09   0.926   0.78    0.446
  rs937283    G vs A            3                            1,710/1,735                      1.02                  0.84--1.24      0.803       67                                               0.048     R   0      1       0.57    0.668
  rs937283    GG vs AA          3                            1,710/1,735                      0.99                  0.69--1.43      0.957       52                                               0.124     R   0      1       0.33    0.795
  rs937283    AG vs AA          3                            1,710/1,735                      1.22                  0.78--1.9       0.377       85.7                                             0.001     R   1.04   0.296   1.05    0.485
  rs937283    AG + GG vs AA     3                            1,710/1,735                      1.17                  0.77--1.77      0.461       85.3                                             0.001     R   1.04   0.296   1.01    0.498
  rs937283    GG vs AA + AG     3                            1,710/1,735                      0.89                  0.74--1.08      0.231       0                                                0.84      F   1.04   0.296   −1.02   0.493
  rs937283    carrier G vs A    3                            1,710/1,735                      1                     0.89--1.12      0.992       9.8                                              0.33      F   0      1       0.59    0.659
  rs3730485   − vs +            3                            709/1,000                        0.89                  0.76--1.04      0.130       0                                                0.428     F   0      1       −0.81   0.567
  rs3730485   −/− vs +/+        3                            709/1,000                        0.82                  0.56--1.19      0.294       0                                                0.7       F   1.04   0.296   −0.69   0.614
  rs3730485   +/− vs +/+        3                            709/1,000                        0.91                  0.73--1.13      0.387       0                                                0.909     F   0      1       0.64    0.637
  rs3730485   +/−, −/− vs +/+   3                            709/1,000                        0.89                  0.73--1.1       0.275       0                                                0.809     F   0      1       −0.53   0.688
  rs3730485   −/− vs +/+, +/−   3                            709/1,000                        0.79                  0.58--1.09      0.146       0                                                0.5       F   0      1       0.62    0.648
  rs3730485   Carrier − vs +    3                            709/1,000                        0.92                  0.77--1.09      0.315       0                                                0.684     F   0      1       −0.81   0.566

**Notes:**

Continuity-corrected; significant *P*-values in bold.

**Abbreviations:** SCC, squamous cell carcinoma; OR, odds ratio; CI, confidence interval; F, fixed-effect model; R, random-effect model.

###### 

Subgroup analysis by ethnicity, source of controls, and HWE for association between *MDM2* rs2279744 and SCC susceptibility

  Comparison                        Ethnicity           HWE                 Source of control                                           
  --------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  G vs T                                                                                                                                
   No of case-control studies       17                  8                   21                  4                   22                  3
   Case/control total sample size   4,414/7,507         3,266/5,136         6,824/11,142        856/1,501           6,555/10,623        1,125/2,020
   OR (95% CI)                      1.12 (1.01--1.24)   1.03 (0.89--1.19)   1.09 (1.01--1.17)   1.09 (0.69--1.71)   1.12 (1.03--1.22)   0.94 (0.72--1.23)
   *P*-value                        **0.027**           0.669               **0.026**           0.711               **0.011**           0.662
  GG vs TT                                                                                                                              
   No of case-control studies       17                  7                   20                  4                   21                  3
   Case/control total sample size   4,414/7,507         3,207/4,976         6,765/10,982        856/1,501           6,496/10,463        1,125/2,020
   OR (95% CI)                      1.26 (1.04--1.52)   1.03 (0.84--1.27)   1.18 (1.03--1.34)   1.13 (0.55--2.34)   1.22 (1.05--1.41)   0.94 (0.58--1.53)
   *P*-value                        **0.016**           0.755               **0.015**           0.74                **0.008**           0.805
  TG vs TT                                                                                                                              
   No of case-control studies       17                  8                   21                  4                   22                  3
   Case/control total sample size   4,414/7,507         3,266/5,136         6,824/11,142        856/1,501           6,555/10,623        1,125/2,020
   OR (95% CI)                      0.97 (0.8--1.1)     0.97 (0.8--1.19)    1.02 (0.89--1.16)   0.87 (0.42--1.77)   1.01 (0.87--1.18)   0.9 (0.6--1.36)
   *P*-value                        0.781               0.805               0.818               0.691               0.857               0.629
  TG + GG vs TT                                                                                                                         
   No of case-control studies       17                  8                   21                  4                   22                  3
   Case/control total sample size   4,414/7,507         3,266/5,136         6,824/11,142        856/1,501           6,555/10,623        1,125/2,020
   OR (95% CI)                      1.06 (0.88--1.28)   1.04 (0.84--1.28)   1.07 (0.95--1.2)    0.94 (0.45--1.94)   1.08 (0.94--1.25)   0.91 (0.6--1.4)
   *P*-value                        0.527               0.736               0.279               0.86                0.269               0.682
  GG vs TT + TG                                                                                                                         
   No of case-control studies       17                  7                   20                  4                   21                  3
   Case/control total sample size   4,414/7,507         3,207/4,976         6,765/10,982        856/1,501           6,496/10,463        1,125/2,020
   OR (95% CI)                      1.25 (1.11--1.42)   1.05 (0.92--1.2)    1.17 (1.06--1.29)   1.27 (0.88--1.83)   1.22 (1.1--1.35)    0.99 (0.78--1.24)
   *P*-value                        \<**0.001**         0.501               **0.002**           0.197               \<**0.001**         0.911
  Carrier G vs T                                                                                                                        
   No of case-control studies       17                  8                   21                  4                   22                  3
   Case/control total sample size   4,414/7,507         3,266/5,136         6,824/11,142        856/1,501           6,555/10,623        1,125/2,020
   OR (95% CI)                      1.08 (1.01--1.16)   1.03 (0.91--1.16)   1.06 (1.01--1.12)   1.07 (0.77--1.5)    1.08 (1.01--1.15)   1.06 (1--1.13)
   *P*-value                        **0.023**           0.672               **0.031**           0.676               **0.018**           0.618

**Note:** Significant *P*-values in bold.

**Abbreviations:** HWE, Hardy--Weinberg equilibrium; SCC, squamous cell carcinoma; PB, population-based; HB, hospital-based; Y, *P*-value of HWE \>0.05; n, *P*-value of HWE \<0.05; OR, odds ratio; CI, confidence interval.

###### 

Subgroup analysis by disease type for association between *MDM2* rs2279744 and SCC susceptibility

  Comparison                        HNSCC               SSCC                ESCC                OSCC                CSCC                LSCC
  --------------------------------- ------------------- ------------------- ------------------- ------------------- ------------------- -------------------
  G vs T                                                                                                                                
   No of case-control studies       3                   2                   6                   5                   3                   5
   Case/control total sample size   1,186/1,210         840/1,525           1,720/2,694         1,369/2,167         657/803             1,605/3,847
   OR (95% CI)                      1.03 (0.92--1.15)   1.16 (1.02--1.32)   1.19 (1.09--1.3)    0.92 (0.81--1.05)   1.19 (0.62--2.25)   1.16 (0.95--1.42)
   *P*-value                        0.659               **0.022**           \<**0.001**         0.223               0.603               0.153
  GG vs TT                                                                                                                              
   No of case-control studies       3                   2                   6                   5                   3                   4
   Case/control total sample size   1,186/1,210         840/1,525           1,720/2,694         1,369/2,167         657/803             1,546/3,687
   OR (95% CI)                      1.03 (0.82--1.31)   1.3 (0.98--1.71)    1.46 (1.23--1.74)   0.86 (0.7--1.07)    1.33 (0.5--3.52)    1.23 (0.92--1.65)
   *P*-value                        0.788               0.067               \<**0.001**         0.173               0.569               0.161
  TG vs TT                                                                                                                              
   No of case-control studies       3                   2                   6                   5                   3                   5
   Case/control total sample size   1,186/1,210         840/1,525           1,720/2,694         1,369/2,167         657/803             1,605/3,847
   OR (95% CI)                      1.02 (0.83--1.26)   1.19 (0.99--1.43)   0.98 (0.72--1.34)   0.82 (0.65--1.04)   0.96 (0.35--0.62)   1.21 (0.88--1.67)
   *P*-value                        0.83                0.062               0.916               0.103               0.941               0.249
  TG + GG vs TT                                                                                                                         
   No of case-control studies       3                   2                   6                   5                   3                   5
   Case/control total sample size   1,186/1,210         840/1,525           1,720/2,694         1,369/2,167         657/803             1,605/3,847
   OR (95% CI)                      1.02 (0.82--1.26)   1.22 (1.02--1.45)   1.14 (0.94--1.38)   0.84 (0.66--1.06)   1.06 (0.39--2.85)   1.26 (0.91--1.75)
   *P*-value                        0.886               **0.028**           0.179               0.135               0.913               0.164
  GG vs TT + TG                                                                                                                         
   No of case-control studies       3                   2                   6                   5                   3                   4
   Case/control total sample size   1,186/1,210         840/1,525           1,720/2,694         1,369/2,167         657/803             1,546/3,687
   OR (95% CI)                      1.01 (0.81--1.26)   1.19 (0.92--1.55)   1.48 (1.12--1.94)   0.98 (0.83--1.16)   1.42 (0.88--2.31)   1.18 (1--1.38)
   *P*-value                        0.911               0.181               **0.005**           0.801               0.154               **0.045**
  Carrier G vs T                                                                                                                        
   No of case-control studies       3                   2                   6                   5                   3                   5
   Case/control total sample size   1,186/1,210         840/1,525           1,720/2,694         1,369/2,167         657/803             1,605/3,847
   OR (95% CI)                      1.02 (0.9--1.16)    1.11 (0.96--1.29)   1.12 (1.01--1.24)   0.94 (0.84--1.06)   1.15 (0.71--1.86)   1.11 (0.92--1.34)
   *P*-value                        0.766               0.148               0.028               0.326               0.581               0.268

**Note:** Significant *P*-values in bold.

**Abbreviations:** HNSCC, head and neck squamous cell carcinoma; SSCC, skin SCC; ESCC, esophageal SCC; OSCC, oral SCC; CSCC, cervical SCC; LSCC, lung SCC; OR, odds ratio; CI, confidence interval.

###### 

Meta-analysis of association between *MDM2ITP53* mutations and SCC susceptibility

  Mutation                         Genotype     No of case-control studies   Case/control total sample size   Test of association   Heterogeneity   Model         Begg[a](#tfn9-ott-9-6211){ref-type="table-fn"}   Egger                                      
  -------------------------------- ------------ ---------------------------- -------------------------------- --------------------- --------------- ------------- ------------------------------------------------ ------- ------- --- ------ ------- ------- -----------
  *MDM2*^+^/TP53^−^                T/G or G/G   Arg/Arg                      5                                1,293/2,375           1.15            0.77--1.72    0.506                                            73.5    0.004   R   1.71   0.086   3.29    **0.046**
  *MDM2^−^/TP5T*                   T/T          Arg/Pro or Pro/Pro           4                                1,017/1,532           0.71            0.5--1        0.051                                            56.9    0.073   R   0.34   0.734   −1      0.424
  *MDM2*^+^/*TP53*^+^, overall     T/G or G/G   Arg/Pro or Pro/Pro           9                                2,474/4,319           1.52            I.I 9--1.95   **0.001**                                        43.1    0.08    R   0.1    0.917   0.1 1   0.918
  *MDM2*^+^/*TP53*^+^, Asian       T/G or G/G   Arg/Pro or Pro/Pro           6                                1,863/2,473           1.49            1.06--2.11    **0.022**                                        50      0.075   R   0      1       −0.75   0.541
  *MDM2*^+^/*TP53*^+^, Caucasian   T/G or G/G   Arg/Pro or Pro/Pro           3                                611/1,846             1.59            0.97--2.61    0.066                                            49.1    0.14    R   1.04   0.296   2.43    **0.022**

**Notes:**

Continuity-corrected; significant *P*-values in bold.

**Abbreviations:** SCC, squamous cell carcinoma; OR, odds ratio; CI, confidence interval; R, random-effect model.
